The Labetalol Hydrochloride Tablets, cataloged under National Stock Number 6505-01-197-4180, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Zenith Laboratories Inc. Government technical data includes 5 specifications, cited from the U.S. Government catalog. The record lists 5 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 8 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. 5 items share a part number with this NSN in the catalog (possible match — not a government interchangeability claim). Current acquisition status: Active. Unit of issue: BT.
| Parameter | Value |
|---|---|
| NSN | 6505-01-197-4180 |
| Primary Part Number | NDC00172-4366-60 |
| Item Name | Labetalol Hydrochloride Tablets |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Zenith Laboratories Inc |
| Status | ACTIVE |
| Coating Feature | FILM, NONENTERIC |
| Primary Container Content Quantity | 100.000 TABLETS |
| Medical Designation and Grade | UNITED STATES PHARMACOPEIA |
| Primary Container Type | BOTTLE |
| Active Medicament Medicinal Strength | 300.000 MILLIGRAMS LABETALOL HYDROCHLORIDE ACTIVE INGREDIENT |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Hazardous per DLA record (HMIC Y) |
| Criticality Code | X |
| Unit of Issue | BT |
| Part Number | Manufacturer |
|---|---|
| NDC00172-4366-60 | Zenith Laboratories Inc (USA) |
| NDC60976-0348-43 | Glaxo Wellcome Inc (USA) |
| NDC00185-0118-01 | Sandoz Inc. (USA) |
| NDC65483-0393-10 | Prometheus Laboratories Inc (USA) |
| NDC00591-0607-01 | Danbury Pharmacal Inc (USA) |
| Reference | Meaning |
|---|---|
| TRANDATE TABLETS | 5/1 Secondary reference Glaxo Wellcome Inc |
| NORMODYNE TABLETS | 5/9 Secondary reference Schering-Plough Corporation |
| TRANDATE | 5/1 Secondary reference Glaxo Wellcome Inc |
| NDC00677-1703-01 | 5/9 Secondary reference Baxter Healthcare Corp Baxter Airlife/pharmaseal Div |
| NDC00185-0118-01 | 5/9 Secondary reference Eon Labs, Inc. |
| NDC00173-0348-43 | 5/9 Secondary reference Glaxo Wellcome Inc |
| NORMODYNE | 5/9 Secondary reference Schering-Plough Corporation |
| NDC00085-0438-03 | 3/9 Design control — primary reference Schering-Plough Corporation |
NSN 6505-01-197-4180 is a Labetalol Hydrochloride Tablets, manufactured by Zenith Laboratories Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-197-4180 has 5 manufacturer part numbers on file: NDC00172-4366-60 (Zenith Laboratories Inc), NDC60976-0348-43 (Glaxo Wellcome Inc), NDC00185-0118-01 (Sandoz Inc.), NDC65483-0393-10 (Prometheus Laboratories Inc), NDC00591-0607-01 (Danbury Pharmacal Inc).
5 possible matches (shared part number, not a government interchangeability claim): 6505-01-208-5995, 6505-01-218-7438, 6505-01-237-0557. Verify interchangeability with system specifications before substitution.
Key specifications for NDC00172-4366-60: Coating Feature: FILM, NONENTERIC; Primary Container Content Quantity: 100.000 TABLETS; Medical Designation and Grade: UNITED STATES PHARMACOPEIA; Primary Container Type: BOTTLE. 5 specifications are documented in the U.S. Government catalog.
Hazardous per DLA record (HMIC Y). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.